Distributor inventory | Tablet
Glimepiride 1 mg + Metformin Hydrochloride 500 mg (sustained/modified release) + Voglibose 0.3 mg
Type 2 diabetes mellitus (adult) when blood sugar is not adequately controlled with diet, exercise and/or single/dual oral antidiabetic therapy; helps control post‑meal and fasting glucose
Glimepiride (a sulfonylurea) increases insulin release from the pancreas. Metformin reduces glucose production in the liver and improves insulin sensitivity. Voglibose inhibits intestinal alpha‑glucosidase enzymes, delaying carbohydrate absorption and reducing post‑meal blood sugar spikes.
Tablet for oral use. Usually taken once daily with food (typically with the first main meal) or as directed by the doctor; swallow whole (do not crush/chew if MR/SR). Follow diet/exercise plan and monitor blood glucose regularly.
Common side effects of ZORYL MV 1/0.3 TAB may include:
Risk of hypoglycaemia (higher with missed meals, alcohol, excessive exercise, elderly, kidney/liver impairment); metformin may rarely cause lactic acidosis—seek urgent care for fast breathing, severe weakness, abdominal pain, unusual sleepiness. Use caution in renal impairment; periodic kidney function tests advised. Hold metformin component before/after iodinated contrast procedures and major surgery as advised by doctor. Avoid in severe renal failure, severe liver disease, alcohol abuse, diabetic ketoacidosis/type 1 diabetes. Monitor for vitamin B12 deficiency with long-term use.
